Navigation Links
Calcium Channel Blocker Adalat GITS Offer Additional Benefits

ACTION-trial shows medical and economic advantages of nifedipine GITS therapy


LEVERKUSEN, Germany, March 28, 2007 – Two recently published articles in the Journal of Clinical Epidemiology provide further evidence that the use of the long-acting calcium channel blocker (CCB) nifedipine GITS (Adalat? GITS) has additional benefits beyond its blood pressure lowing effect. A first publication from Lubsen et al. (Journal of Clinical Epidemiology 2007; first published online) demonstrates that while the blood pressure lowering effect of nifedipine GITS did play a major role in the reduction of debilitating stroke and new overt heart failure, the anti-anginal and vascular protective effects of nifedipine GITS seem to be just as important in reducing cardiovascular events. A second publication by Poole-Wilson et al. (Journal of Clinical Epidemiology 2007; first published online) also demonstrates that a nifedipine GITS therapy in patients with stable angina can help contain healthcare expenses by reducing the need for additional medication and the use of expensive diagnostic and surgical procedures. Both these papers are based on analyses of the ACTION-database. ACTION (A Coronary Disease Trial Investigating Outcome with Nifedipine GITS) collected data from 7,665 patients with stable angina pectoris.

Lowering blood pressure helps reduce stroke and heart failure
The ACTION-trial showed that adding nifedipine GITS to a best practice angina pectoris therapy significantly reduced the incidence of any stroke or TIA (28%) and the development of new overt heart failure (29%). Using an innovative statistical approach, Lubsen et al. found that nifedipine GITS’ ability to lower systolic blood pressure was largely responsible for these impressive results. The reduction in the risks of coronary angiography and surgery, attributed to nifedipine GITS on the other hand, are likely to be d ue to an anti-anginal and a vascular protective effect.


Efficient utilization of resources
Using the ACTION data, Poole-Wilson et al. showed that adding nifedipine GITS to the best practice therapy reduced the need for additional medication and also the use of expensive diagnostic and surgical procedures together with their associated costs. Basis for the calculation of hospital expenses was a reference hospital in the Netherlands. The estimated cost of medication was also based on drug pricing in the Netherlands. In total the incremental cost of the nifedipine GITS therapy was just about € 69 per year, or about € 3,036 per year of event free survival.


Bayer HealthCare
Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG, Germany. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide.

Bayer Schering Pharma
Bayer Schering Pharma AG, Germany, is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, Hematology/Cardiology, Oncology, Primary Care, Specialized Therapeutics and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life.

Forward-looking statements
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known an d unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'"/>




Related medicine technology :

1. Calcium Plaque Build-up in the Arteries Leads to Coronary Heart Disease in Multi-Ethnic Groups
2. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
3. Analyzers Offer Point-of-Care Lipid Panels
4. Ties Between Physicians and Drug Companies Still Too Strong: the Prescription Project Offers Solutions to Prevent Conflicts of Interest
5. Novel Human Tissue Transgenic Cancer Model May Offer Significant Advance Toward Accurately Modeling Human Cancer
6. MUSC Research Offers Hope for Those Resistant to Depression Treatment
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
10. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
11. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... -- Research and Markets has announced the addition of the ... their offering. ... separate comprehensive analytics for the US, Canada , ... , and Rest of World. Annual estimates and forecasts are provided ... provided for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Feb. 17, 2017  Featuring new ... at the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  ... a global leader in health ... of population health management, acute healthcare ... integrated in a highly secure, cloud-based ...
(Date:2/16/2017)... , Feb. 16, 2017 Research and ... for Emerging Medical Device Technologies" report to their offering. ... ... open procedures, general instruments, non-drug coated implantables, large endoscopes, needle ... in use over the last two to three decades for ...
Breaking Medicine Technology:
(Date:2/17/2017)... BEAVER CREEK, CO (PRWEB) , ... February 17, 2017 , ... ... the second annual International Healing NET Foundation Summit from February 21 - 23 in ... Healing NET Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting ...
(Date:2/17/2017)... ... February 17, 2017 , ... Dillon Ruxton Insurance, a Florida-based ... owners in the greater Fort Lauderdale metropolitan region, is embarking on a cooperative ... 30 years, LifeNet 4 Families has provided a broad range of food provision ...
(Date:2/16/2017)... ... February 17, 2017 , ... For some cancer survivors, ... final treatments. Physician researchers at The Marcus Institute of Integrative Health at ... efficacy in reducing symptoms of traumatic stress in cancer patients and published ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... financial planning services to families and entrepreneurs in the Birmingham area, is announcing ... mother who needs assistance with her medically challenged son, Anius. , Anius is ...
(Date:2/16/2017)... ... 16, 2017 , ... Doctors on Liens is proud to ... network through his work at BKP Chiropractic in Lancaster . After ... from Canada’s prestigious International Baccalaureate Program, Dr. Raj went on to open successful ...
Breaking Medicine News(10 mins):